1,935 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Texas Yale Capital Corp.

Texas Yale Capital Corp. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,935 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Other institutional investors have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences during the first quarter valued at $25,000. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences during the first quarter valued at $29,000. Annis Gardner Whiting Capital Advisors LLC grew its position in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 216 shares during the period. Core Alternative Capital grew its position in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 241 shares during the period. Finally, IMA Advisory Services Inc. acquired a new stake in Gilead Sciences during the first quarter valued at $39,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on GILD shares. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price target on the stock. Oppenheimer dropped their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Finally, Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research report on Friday. Eight research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $112.36.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider directly owned 121,152 shares in the company, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the transaction, the chief financial officer owned 162,610 shares in the company, valued at $18,054,588.30. The trade was a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,000 shares of company stock valued at $7,844,775. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $113.03 on Tuesday. The firm has a market capitalization of $140.60 billion, a PE ratio of 23.80, a PEG ratio of 0.73 and a beta of 0.29. Gilead Sciences, Inc. has a twelve month low of $72.43 and a twelve month high of $119.96. The firm’s 50-day moving average price is $110.04 and its 200 day moving average price is $106.28. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.